SONIRE Therapeutics Inc.
PrivateLast Round
Series A
Apr 15, 2026
Est. Valuation
$36.2M
Total Funding Raised
$39.84M
Momentum Score
25 /100
Company Overview
SONIRE Therapeutics Inc. is a Japanese medical device company founded in February 2020 that is developing a next-generation ultrasound-guided High-Intensity Focused Ultrasound (HIFU) therapy system. The technology, which originated from research at Tokyo Women's Medical University, Tohoku University, and Tokyo Medical University, is designed to treat intractable cancers, with an initial focus on pancreatic cancer. The company's system, codenamed 'Suizenji', aims to provide a non-invasive treatment that can be performed without anesthesia and poses no radiation exposure risk. SONIRE is actively conducting clinical trials in Japan and is preparing for trials in the U.S. The company has raised approximately JPY 3.1 billion through funding rounds, including a Series B in November 2022. Its HIFU system received Breakthrough Device Designation from the U.S. FDA for the treatment of pancreatic cancer.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials, Precision Medicine, Medical Imaging
Business Model
B2B
Customer Profile
Hardware Sales, Hardware + Subscription, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SONIRE Therapeutics Inc. Comps
Public and private peers based on sector, stage, and business model.
SONIRE Therapeutics Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 15, 2026 | ||||
| Series B | Nov 30, 2022 | ||||
| Series A | Jun 11, 2021 |
Key People
Founding team and executive leadership
SONIRE Therapeutics Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| QR Investment Co., Ltd. | Series B |
| Japan Growth Capital | Series B |
| Santé Ventures | Series A |
| epiST Ventures Inc. | Series A |
| Japan Growth Capital Investment Corporation | Series A |
| Nomura Sparks Investment | Series A |
| Carbon Ventures | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 15, 2026
Raised Series A to advance non-invasive tumor ablation system.
- Apr 15, 2026
Expanded corporate footprint by establishing a new headquarters in Palo Alto, California.
SONIRE Therapeutics Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about SONIRE Therapeutics Inc.'s valuation, stock price, and market status.
